ACTEMRA® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of rheumatoid arthritis (RA), giant cell arthritis (GCA), systemic sclerosis-associated interstitial lung disease (SSc-ILD), polyarticular juvenile idiopathic arthritis (PJIA), and systemic juvenile idiopathic arthritis (SJIA), and cytokine release syndrome (CRS). This medication is available as an infusion or a subcutaneous injection.

AMVUTTRA® (vutrisiran) is a small interfering RNA (siRNA) therapeutic indicated for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. This medication reduces the production of transthyretin (TTR) protein through RNA interference and is administered as a subcutaneous injection once every 3 months.

AVSOLA® (infliximab-axxq) is a TNF-alpha inhibitor indicated for the treatment of rheumatoid arthritis (RA), crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis

BENLYSTA® (belimumab) is a B-lymphocyte stimulator (BLyS) inhibitor indicated for the treatment of systemic lupus erythematosus (SLE) in autoantibody-positive adult patients, and active lupus nephritis

CIMZIA® (certolizumab pegol) is a TNF-alpha inhibitor indicated for the treatment of rheumatoid arthritis (RA), Crohn's disease, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis

ENTYVIO® (vedolizumab) is an integrin receptor antagonist indicated for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease

EVENITY® (romosozumab-aqqg) is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture

FASENRA® (benralizumab) is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody indicated for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype and eosinophillic granulomatosis with polyangiitis (EGPA)

FERAHEME®, INJECTAFER®, and VENOFER® are iron replacement products indicated for the treatment of iron deficiency anemia or for anemia related to chronic kidney disease

GAMMAGARD LIQUID® [Immune Globulin Infusion (Human) 10%] is an immune globulin indicated for the treatment of primary immunodeficiency (PI) in adults and children 2 years and older, maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP), and multifocal motor neuropathy (MMN) in adults